Yisheng Biopharma, a Beijing vaccine company, will collaborate with the United States Army Medical Research Institute of Infectious Diseases to develop an Ebola vaccine using Yisheng’s proprietary PKA adjuvant. The agreement was signed between the USAMRIID and Yisheng’s US subsidiary. Apparently, both entities will have rights to vaccines developed by the collaboration, for either Ebola or other viruses.
